Literature DB >> 12895595

BLT1 and BLT2: the leukotriene B(4) receptors.

Andrew M Tager1, Andrew D Luster.   

Abstract

Two receptors for leukotriene B(4) (LTB(4)) have been molecularly identified: BLT1 and BLT2. Both receptors are G protein-coupled seven transmembrane domain receptors, whose genes are located in very close proximity to each other in the human and mouse genomes. The two receptors differ in their affinity and specificity for LTB(4): BLT1 is a high-affinity receptor specific for LTB(4), whereas BLT2 is a low-affinity receptor that also binds other eicosanoids. The two receptors also differ in their pattern of expression with BLT1 being expressed primarily in leukocytes, whereas BLT2 is expressed more ubiquitously. By mediating the activities of LTB(4), these receptors participate both in host immune responses and in the pathogenesis of inflammatory diseases. Reduced disease severity in animal inflammatory models seen with LTB(4) receptor antagonists and in mice with targeted deletion of BLT1 have revealed important roles for LTB(4) and its receptors in regulating pathologic inflammation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895595     DOI: 10.1016/s0952-3278(03)00073-5

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  109 in total

1.  Leukotriene b4 and its metabolites prime the neutrophil oxidase and induce proinflammatory activation of human pulmonary microvascular endothelial cells.

Authors:  John C Eun; Ernest E Moore; Anirban Banerjee; Marguerite R Kelher; Samina Y Khan; David J Elzi; Nathan J D McLaughlin; Christopher C Silliman
Journal:  Shock       Date:  2011-03       Impact factor: 3.454

Review 2.  Bioactive lipoxygenase metabolites stimulation of NADPH oxidases and reactive oxygen species.

Authors:  Kyung-Jin Cho; Ji-Min Seo; Jae-Hong Kim
Journal:  Mol Cells       Date:  2011-03-18       Impact factor: 5.034

3.  Blocking the leukotriene B4 receptor 1 inhibits late-phase airway responses in established disease.

Authors:  Koichi Waseda; Nobuaki Miyahara; Arihiko Kanehiro; Genyo Ikeda; Hikari Koga; Yasuko Fuchimoto; Etsuko Kurimoto; Yasushi Tanimoto; Mikio Kataoka; Mitsune Tanimoto; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2011-03-18       Impact factor: 6.914

4.  Leukotriene Inhibitors in Sinusitis.

Authors:  John W Steinke; Joshua L Kennedy
Journal:  Curr Infect Dis Rep       Date:  2012-01-29       Impact factor: 3.725

5.  Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis.

Authors:  Richard C Li; Bodduluri Haribabu; Steven P Mathis; Jinkwan Kim; David Gozal
Journal:  Am J Respir Crit Care Med       Date:  2011-04-14       Impact factor: 21.405

Review 6.  Phagocyte partnership during the onset and resolution of inflammation.

Authors:  Oliver Soehnlein; Lennart Lindbom
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

7.  RanBPM protein acts as a negative regulator of BLT2 receptor to attenuate BLT2-mediated cell motility.

Authors:  Jun-Dong Wei; Joo-Young Kim; Ae-Kyoung Kim; Sung Key Jang; Jae-Hong Kim
Journal:  J Biol Chem       Date:  2013-08-08       Impact factor: 5.157

8.  Leukotrienes enhance the bactericidal activity of alveolar macrophages against Klebsiella pneumoniae through the activation of NADPH oxidase.

Authors:  Carlos H C Serezani; David M Aronoff; Sonia Jancar; Peter Mancuso; Marc Peters-Golden
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

9.  Leukotriene A4 Hydrolase Activation and Leukotriene B4 Production by Eosinophils in Severe Asthma.

Authors:  Kavita Pal; Xin Feng; John W Steinke; Marie D Burdick; Yun M Shim; Sun-Sang Sung; W Gerald Teague; Larry Borish
Journal:  Am J Respir Cell Mol Biol       Date:  2019-04       Impact factor: 6.914

10.  The transcriptome of the fetal inflammatory response syndrome.

Authors:  Sally A Madsen-Bouterse; Roberto Romero; Adi L Tarca; Juan Pedro Kusanovic; Jimmy Espinoza; Chong Jai Kim; Jung-Sun Kim; Samuel S Edwin; Ricardo Gomez; Sorin Draghici
Journal:  Am J Reprod Immunol       Date:  2010-01       Impact factor: 3.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.